HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
about
Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analysesSelective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexesPreclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitroResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesAnti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptasePreclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replicationIdentification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virusMode of inhibition of HIV reverse transcriptase by 2-hexaprenylhydroquinone, a novel general inhibitor of RNA-and DNA-directed DNA polymerasesMolecular docking of (5E)-3-(2-aminoethyl)-5-(2- thienylmethylene)-1, 3-thiazolidine-2, 4-dione on HIV-1 reverse transcriptase: novel drug acting on enzyme.Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.Estimation of Anti-HIV Activity of HEPT Analogues Using MLR, ANN, and SVM Techniques.Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compoundsAntiviral therapy for human immunodeficiency virus infectionsInhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells.Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase.Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase.The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking.Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.Prospects for rational approaches to anthelmintic discovery.Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition.Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics.Inhibitory effects of Korean plants on HIV-1 activities.Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase.Pharmacokinetics of Succinylated Serum Albumin in Wistar Rats and Cynomolgus Monkeys: Implications for Dosage Regimens in the Therapy of HIV Infection.(s4dU)35: a novel, highly potent oligonucleotide inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro.Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.From TIBO to Rilpivirine: The Chronicle of the Discovery of the Ideal Nonnucleoside Reverse Transcriptase InhibitorHiv-1 Specific Reverse Transcriptase Inhibitors: why are Tsao-Nucleosides so Unique?
P2860
Q24540388-D36A704D-7991-4CA4-9DA3-C8BE70A0182EQ27621483-3F66C1E5-8824-48E3-9FBE-0EABBD916F34Q28344140-020BE2CE-EBDA-4870-9680-E72578B75BD9Q28367573-0406E1DA-CABB-40AF-9D78-9432C6C8072AQ28368381-629801B3-1D6F-425A-A17F-E64F69B7B391Q28378745-83F6EEBD-1DCC-4E4F-8125-A17804EAEF95Q28378825-36517462-75CA-42C4-9ED8-BD2739980B67Q28379002-1051B362-F24D-49E7-BEC3-2FFBF554F8A0Q28379011-F6F46DE0-461B-4905-A6BA-5CEB1C86447DQ30422172-EAA02111-8FBD-4446-9CF7-C73444B4A08AQ33873983-EF2595F6-B5B0-486A-8FAA-60A33E472B2EQ33976004-D3E73BB2-4E87-4D02-BB69-9586725223B1Q33978490-20EB839B-F4AC-4568-B3E5-4EDE0D7CFFF2Q34145448-7B77B2BB-11B8-40A0-806A-A71FBE49E457Q34393456-81A87CE0-EDD0-4811-87FE-4B6648CDB0E7Q35123273-FD653BA8-5AC5-41B3-9E12-EE784517E93DQ35366050-E76AAE02-585C-44C4-9B2E-97205A16D2B5Q37470888-9796B826-4163-4B1D-A932-810F1B8E3339Q38297932-2176F575-FB95-4E99-88D2-3CB8C962DE23Q38339368-0D9C700F-9BD7-4350-BC12-55E8D489058EQ39723479-52777030-C76C-4282-B02D-3783AFC37D7BQ40042904-2B47432A-2E2C-420B-8511-0C85D786E466Q40534064-E3BF6E04-5047-44D5-810F-A8ECC2D10763Q40683523-90F35358-B531-4720-9B10-69EA4D41D5E8Q40816072-B44C50EC-B488-4F22-A8DA-CE80E4678F13Q40985925-20167AED-7B79-4A38-92B7-0DF5126D3A5DQ41176946-A7439294-5332-48E0-BB87-2728AFB51CBBQ41365181-E29F37A0-75BC-4537-96FC-64EA6964E6E3Q41695558-AF4FAD86-BBF3-4F7A-B4D4-0835CCEB8D26Q42198524-5CD469AE-E9B9-4207-B936-B43646E94C70Q42281612-B2C107E5-D785-430A-A8CA-74BEB22A6FA6Q43649655-6E5CC298-E4FF-4DF9-9481-E9CC28126408Q44250812-80B79353-61E2-4E7E-A88E-FFF7F2C4831CQ45205393-7419D509-9C4B-4857-8FBD-5A224812C323Q45766599-E0AADCC7-4AD4-4B6B-8D11-5ED65E9C2030Q45768310-19FF1F21-97E1-4CB9-9D7F-2FFA375E7459Q47576341-52AC829C-B225-4ACD-94D1-2A61F4110D58Q56786251-E23C2C8D-B990-4C89-B734-891E08509AF1Q57966461-25BC453A-5B2E-48A2-A55F-5A1B4B7E5EFF
P2860
HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
HIV-1-specific RT inhibitors: ...... e viral reverse transcriptase.
@en
type
label
HIV-1-specific RT inhibitors: ...... e viral reverse transcriptase.
@en
prefLabel
HIV-1-specific RT inhibitors: ...... e viral reverse transcriptase.
@en
P2860
P356
P1476
HIV-1-specific RT inhibitors: ...... e viral reverse transcriptase.
@en
P2093
De Clercq E
P2860
P304
P356
10.1002/MED.2610130303
P577
1993-05-01T00:00:00Z